GEN Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
EN
13/10/2020

Underlying

GENGenmab A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genmab A/S

 PRESS RELEASE
Free
GEN GENMAB A/S

Transactions with Shares and Linked Securities in Genmab A/S Made by M...

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; April 1, 2026 – (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse, Genmab A/S publishes transactions in shares and linked securities issued by Genmab A/S by managerial employees and their closely associated persons. The transactions con...

April 1, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Major Shareholder Announcement

Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 1, 2026 – (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 31, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,221,620 shares in Genmab A/S, which amounts to 5.01% of the share capital and voting rights in Genmab A/S.   The major shareholder announcement of Orbis Investment Management Limited is attached to t...

April 1, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Major Shareholder Announcement

Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 27, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,205,763 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S.   The major shareholder announcement of Orbis Investment Management Limited is attached to ...

March 30, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Completion of Share Buy-back Program

Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026. On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of 725 million DKK to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than March 31, 2026. The following transactions were executed under the program from Mar...

March 16, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than March 31, 2026. The following transactions were executed under the program from March 2 to March 6, 2026:  No. of sharesAverage price (DKK)Tot...

March 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch